Regen med therapeutic opportunities for fighting COVID-19-Reference-Cited by-同舟云学术

Regen med therapeutic opportunities for fighting COVID-19

Published:2020-08-27 Issue:1 Volume:10 Page:5-13
ISSN:2157-6564
Container-title:Stem Cells Translational Medicine
language:en
Short-container-title:

Author:

Atala Anthony¹,Henn Alicia²,Lundberg Martha³,Ahsan Taby⁴,Greenberg Jordan⁵,Krukin Jeff⁶,Lynum Steven⁷,Lutz Cat⁸,Cetrulo Kyle⁹,Albanna Mohammad¹⁰,Pereira Taciana¹¹,Eaker Shannon¹²,Hunsberger Joshua¹³

Affiliation:

1. Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA

2. Biospherix, Lacona, New York, USA

3. National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, USA

4. RoosterBio, Frederick, Maryland, USA

5. Organabio, Miami, Florida, USA

6. Orbital Transports, Chicago, Illinois, USA

7. PHC Group, Livingston, New Jersey, USA

8. Jackson Labs, Mount Desert Island, Maine, USA

9. International Perinatal Stem Cell Society, Inc., Westport, Connecticut, USA

10. Humabiologics, Inc., Phoenix, Arizona, USA

11. Allevi, Philadelphia, Pennsylvania, USA

12. Cytiva, Marlborough, Massachusetts, USA

13. Regenerative Medicine Manufacturing Society, Winston-Salem, North Carolina, USA

Abstract

Abstract This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.

Funder

U.S. Department of Health and Human Services

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Cell Biology,Developmental Biology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/sctm.20-0245

Reference73 articles.

1. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City;Petrilli;BMJ,2020

2. SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: A novel COVID phenotype in children;Licciardi;Pediatrics,2020

3. SARS-CoV-2, which induces COVID-19, causes Kawasaki-like disease in children: Role of pro-inflammatory and anti-inflammatory cytokines;Ronconi;J Biol Regul Homeost Agents,2020

4. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: An observational cohort study;Verdoni;Lancet,2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review;Biologics: Targets and Therapy;2023-05

2. Insights into organoid-based modeling of COVID-19 pathology;Virology Journal;2023-02-25

3. A comparative analysis on the safety and efficacy of Covaxin versus other vaccines against COVID-19: a review;Zeitschrift für Naturforschung C;2022-03-02

4. Detection of SARS-Cov-2 N-protein in Mesenchymal Cells of Umbilical Warton's Jelly in Women with COVID-19;Biomedical Chemistry: Research and Methods;2022

5. Recent Advances of COVID-19 Modeling Based on Regenerative Medicine;Frontiers in Cell and Developmental Biology;2021-10-25